Entera Bio Ltd. raises $275 million in oversubscribed private Placement to fund EB613 development, with shares up 62.1% year-to-date. This funding boost positions the company for a potential NDA submission.

Key Highlights

  • Entera Bio Ltd. has raised $275 million in an oversubscribed private placement to advance its lead candidate EB613.
  • The company's shares are up 62.1% year-to-date and 68.8% over the past month.
  • Entera Bio Ltd.'s cash resources are expected to be sufficient to fund the company's operations into 2030.

Entera Bio Ltd. ( Nasdaq : ENTX) has raised $275 million in an oversubscribed private placement, providing the company with sufficient funds to advance its lead candidate, EB613, an oral anabolic tablet for osteoporosis, through a potential New Drug Application (NDA) submission. Comparative anchor: ENTX reported EPS of $-0.14 for the quarter ended 2026-06-30, against a $-0.08 consensus estimate. This funding boost positions Entera Bio Ltd. for a significant milestone in its development pipeline, with shares up 62.1% year-to-date and 68.8% over the past month.

Private Placement Details

Entera Bio Ltd.'s cash resources, including $11.3 million in cash equivalents and $7.1 million in restricted cash, are expected to be sufficient to fund the company's operations into 2030. This funding boost reduces the company's reliance on external financing and provides a stable foundation for its development pipeline.

EB613 Development Update

Entera Bio Ltd.'s lead candidate, EB613, is an oral anabolic tablet for osteoporosis, a condition that affects millions of postmenopausal women worldwide.

Market Context and Performance

Entera Bio Ltd.'s shares have performed strongly, up 62.1% year-to-date and 68.8% over the past month, with a market Capitalization of $141 million. The company's 52-week range is $0.91 to $4.20. Sector peers URGN and KMDA are down 0.4% on the day, providing a mixed read-through for the industry.

Entera Bio Ltd.'s funding boost and pipeline progress position the company for potential Long-term Growth , with the private placement reducing the company's financing risk and providing a stable foundation for its development pipeline.

Next Catalyst

The next catalyst for Entera Bio Ltd. is the ASBMR 2026 Annual Meeting, scheduled to take place from October 9-12, 2026, in Boston, Massachusetts. This presentation will provide further insight into the efficacy and safety of EB613, potentially influencing investor sentiment and the company's stock price. With the private placement providing sufficient funding, Entera Bio Ltd. is well-positioned to advance its pipeline and achieve significant milestones in the coming months.

Peers Moving on This News

  • Urogen Pharma Ltd (URGN) down 0.4%
  • Kamada Ltd (KMDA) down 0.4%

Analysis based on the Form 8-K filed 7 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.